Adrenoleukodystrophy: Recent advances in treatment and disease etiology

Future Lipidology

Volumn 4, Issue 2, 2009, Pages 205-213

  Drover, Victor A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

ABCDI; Adrenoleukodystrophy; Demyelination; Hematopoietic stem cell transplantation; Oxidative stress; Peroxisome; Very long chain fatty acid

Indexed keywords

ABC TRANSPORTER; ADAPTOR PROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN; PROTEIN PEX5; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADRENOLEUKODYSTROPHY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE COURSE; DISEASE SEVERITY; EVOKED MUSCLE RESPONSE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; PATHOGENESIS; PATIENT SAFETY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 67249113427     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.11     Document Type: Review

References (43)

1. Moser HW, Mahmood A, Raymond GV: X-linked adrenoleukodystrophy. Nat. Clin. Pract. Neurol. 3, 140-151 (2007).
2. Moser HW: Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120 (Pt 8), 1485-1508 (1997).
3. Whitcomb RW, Linehan WM, Knazek RA: Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J. Clin. Invest. 81, 185-188 (1988).
4. Powers JM, Schaumburg HH: The adrenal cortex in adreno-leukodystrophy. Arch. Pathol. 96, 305-310 (1973).
5. Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K: Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem. 26, 851-860 (1976).
6. Lazo O, Contreras M, Bhushan A, Stanley W, Singh I: Adrenoleukodystrophy: impaired oxidation of fatty acids due to peroxisomal lignoceroyl-CoA ligase deficiency. Arch. Biochem. Biophys. 270, 722-728 (1989).
7. Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I: Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc. Natl Acad. Sci. USA 85, 7647-7651 (1988).
8. Singh I, Lazo O, Dhaunsi GS, Contreras M: Transport of fatty acids into human and rat peroxisomes. Differential transport of palmitic and lignoceric acids and its implication to X-adrenoleukodystrophy. J. Biol. Chem. 267, 13306-13313 (1992).
9. Wanders RJ, van Roermund CW, van Wijland MJ et al.: Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem. Biophys. Res. Commun. 153, 618-624 (1988).
10. Hashmi M, Stanley W, Singh I: Lignoceroyl-CoASH ligase: enzyme defect in fatty acid β-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Lett. 196, 247-250 (1986).
11. Mosser J, Douar AM, Sarde CO et al.: Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361, 726-730 (1993).
12. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42, 1007-1017 (2001).
13. van Roermund CW, Visser WF, Ijlst L et al.: The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J. 22 (12), 4201-4208 (2008).
14. Steinberg SJ, Kemp S, Braiterman LT, Watkins PA: Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. Ann. Neurol. 46, 409-412 (1999).
15. Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond GV: 'Lorenzo's oil' therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J. Mol. Neurosci. 33, 105-113 (2007).
16. Pai GS, Khan M, Barbosa E et al.: Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol. Genet. Metab. 69, 312-322 (2000).
17. Aubourg P, Blanche S, Jambaque I et al.: Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleuko-dystrophy by bone marrow transplantation. N. Engl. J. Med. 322, 1860-1866 (1990).
18. Shapiro E, Krivit W, Lockman L et al.: Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356, 713-718 (2000).
19. Peters C, Charnas LR, Tan Y et al.: Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 104, 881-888 (2004).
20. Schonberger S, Roerig P, Schneider DT, Reifenberger G, Gobel U, Gartner J: Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. Arch. Neurol. 64, 651-657 (2007).
21. Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW: Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 6, 687-692 (2007).
22. Loes DJ, Hite S, Moser H et al.: Adrenoleukodystrophy: a scoring method for brain MR observations. Am. J. Neuroradiol. 15, 1761-1766 (1994).
23. Moser HW, Tutschka PJ, Brown FR 3rd et al.: Bone marrow transplant in adrenoleukodystrophy. Neurology 34, 1410-1417 (1984).
24. Moser AB: Newborn screening for X-linked adrenoleukodystrophy on the horizon. Pediatric News 42, 32-33 (2008).
25. Hitomi T, Mezaki T, Tomimoto H et al.: Long-term effect of bone marrow transplantation in adult-onset adrenoleukodystrophy. Eur. J. Neurol. 12, 807-810 (2005).
26. Fitzpatrick AS, Loughrey CM, Johnston P et al.: Haematopoietic stem-cell transplant for adult cerebral adrenoleukodystrophy. Eur. J. Neurol. 15, E21-E22 (2008).
27. Resnick IB, Abdul Hai A, Shapira MY et al.: Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen. Clin. Transplant 19, 840-847 (2005).
28. Okamura K, Watanabe T, Onishi T et al.: Successful allogeneic unrelated bone marrow transplantation using reduced-intensity conditioning for the treatment of X-linked adrenoleukodystrophy in a one-yr-old boy. Pediatr. Transplant 13(1), 130-133 (2008).
29. Martin PL, Carter SL, Kernan NA et al.: Results of the Cord Blood Transplantation Study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol. Blood Marrow Transplant 12, 184-194 (2006).
30. Ho JK, Moser H, Kishimoto Y, Hamilton JA: Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J. Clin. Invest. 96, 1455-1463 (1995).
31. Knazek RA, Rizzo WB, Schulman JD, Dave JR: Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J. Clin. Invest. 72, 245-248 (1983).
32. Dumser M, Bauer J, Lassmann H, Berger J, Forss-Petter S: Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency. Acta Neuropathol. 114, 573-586 (2007).
33. Pan B, Fromholt SE, Hess EJ et al.: Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp. Neurol. 195, 208-217 (2005).
34. Kassmann CM, Lappe-Siefke C, Baes M et al.: Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 39, 969-976 (2007).
35. Baes M, Gressens P, Baumgart E et al.: A mouse model for Zellweger syndrome. Nat. Genet. 17, 49-57 (1997).
36. Deon M, Sitta A, Barschak AG et al.: Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. Int. J. Dev. Neurosci. 25, 441-444 (2007).
37. Vargas CR, Wajner M, Sirtori LR et al.: Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim. Biophys. Acta 1688, 26-32 (2004).
38. Deon M, Sitta A, Barschak AG et al.: Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. J. Neurol. Sci. 266, 79-83 (2008).
39. Fourcade S, Lopez-Erauskin J, Galino J et al.: Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol. Genet. 17(12), 1762-1773 (2008).
40. Singh J, Khan M, Singh I: Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J. Lipid Res. 50(1), 135-147 (2008).
41. Lu JF, Barron-Casella E, Deering R et al.: The role of peroxisomal ABC transporters in the mouse adrenal gland: the loss of Abcd2 (ALDR), not Abcd1 (ALD), causes oxidative damage. Lab. Invest. 87, 261-272 (2007).
42. Drover VA, Nguyen DV, Bastie CC et al.: CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. J. Biol. Chem. 283, 13108-13115 (2008).
43. Sheikh FG, Pahan K, Khan M, Barbosa E, Singh I: Abnormality in catalase import into peroxisomes leads to severe neurological disorder. Proc. Natl Acad. Sci. USA 95, 2961-2966 (1998)